A Bacterial Signature Shared by Normal Aging and Parkinson's Narrows Where Prevention Might Start

A review of 46 gut microbiome studies finds two bacterial genera rising and two falling in both healthy aging and Parkinson's disease, while one marker shifts only with the disease, a pattern researchers say could help separate age related change from disease specific risk.

A review published in Frontiers in Aging Neuroscience on March 13, 2026 reports that the gut bacteria genera Akkermansia and Alistipes increase in both ordinary aging and Parkinson's disease, while Faecalibacterium and Blautia decrease in both, a pattern the authors, led by Teddy Jia Wei Tng at Singapore's Lee Kong Chian School of Medicine and the National Neuroscience Institute, say held across the full range of Parkinson's symptom severity. Faecalibacterium and Blautia are known producers of butyrate, a short chain fatty acid with anti-inflammatory effects in the gut, so the authors propose that its depletion may be a thread connecting aging and Parkinson's rather than a marker of Parkinson's alone.

The paper is a review, not a new patient study. The team screened 689 PubMed records on Parkinson's gut microbiome published between 2017 and 2022 using 16S rRNA sequencing of fecal samples, narrowing to 35 original studies spanning 12 countries and patients aged 52 to 88. They compared this against 11 studies of aging gut microbiota, from young adults through centenarians, across seven countries. A separate search of the terms Parkinson's and butyrate covering 2021 to 2025 turned up 67 publications, which the authors cite as evidence of growing interest in the metabolite as a mechanism.

Not every shift was shared. The review describes a decline in Prevotellaceae, a bacterial family, as unique to Parkinson's and not part of the general aging pattern, a divergence the authors flag as potentially more specific to the disease than to age itself. A separate 2025 review in Frontiers in Neuroscience, by Pfaffinger and colleagues, had already noted elevated Akkermansia as one of the more consistently reported findings across Parkinson's cohort studies, which lends some corroboration to that part of the picture without resolving what drives it.

The Singapore team's own caution is central to how the finding should be read: the underlying studies were cross-sectional and case-control, comparing different people at a single point in time rather than following the same individuals as they aged or as disease progressed. Diet, reduced mobility, and medication use are common to both aging and Parkinson's and could independently produce overlapping bacterial shifts without either condition causing the other.

The authors call for future work that tracks the same people over time and statistically separates age related change from disease specific change before any bacterial signature is treated as an early marker or a target for intervention.